ATE234282T1 - Polymorphe verbindungen - Google Patents

Polymorphe verbindungen

Info

Publication number
ATE234282T1
ATE234282T1 AT97929654T AT97929654T ATE234282T1 AT E234282 T1 ATE234282 T1 AT E234282T1 AT 97929654 T AT97929654 T AT 97929654T AT 97929654 T AT97929654 T AT 97929654T AT E234282 T1 ATE234282 T1 AT E234282T1
Authority
AT
Austria
Prior art keywords
pct
fluvastatin sodium
fluvastatin
sodium form
sec
Prior art date
Application number
AT97929654T
Other languages
English (en)
Inventor
Karol Horvath
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9602477A external-priority patent/SE9602477D0/xx
Priority claimed from SE9700751A external-priority patent/SE9700751D0/xx
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE234282T1 publication Critical patent/ATE234282T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
AT97929654T 1996-06-24 1997-06-18 Polymorphe verbindungen ATE234282T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9602477A SE9602477D0 (sv) 1996-06-24 1996-06-24 Polymorphic compounds
SE9700751A SE9700751D0 (sv) 1997-03-03 1997-03-03 Polymorphic compounds
PCT/SE1997/001097 WO1997049681A1 (en) 1996-06-24 1997-06-18 Polymorphic compounds

Publications (1)

Publication Number Publication Date
ATE234282T1 true ATE234282T1 (de) 2003-03-15

Family

ID=26662685

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97929654T ATE234282T1 (de) 1996-06-24 1997-06-18 Polymorphe verbindungen

Country Status (11)

Country Link
US (1) US6124340A (de)
EP (1) EP0907639B1 (de)
JP (2) JP4282092B2 (de)
AT (1) ATE234282T1 (de)
AU (1) AU3366297A (de)
CY (1) CY2461B1 (de)
DE (1) DE69719755T2 (de)
DK (1) DK0907639T3 (de)
ES (1) ES2194202T3 (de)
PT (1) PT907639E (de)
WO (1) WO1997049681A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902202D0 (sv) * 1999-06-10 1999-06-10 Astra Ab Production of aggregates
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
JP2004513112A (ja) 2000-10-31 2004-04-30 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド フルバスタチンナトリウムの結晶形
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
PL366905A1 (en) * 2001-08-03 2005-02-07 Ciba Specialty Chemicals Holding Inc. Crystalline forms of fluvastatin sodium
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
DE10316087A1 (de) * 2003-04-08 2004-11-11 Ratiopharm Gmbh Polymorphstabilisierung von Fluvastatin-Natrium in Pharmazeutischen Formulierungen
WO2004096765A2 (en) * 2003-05-01 2004-11-11 Morepen Laboratories Ltd. A novel crystalline polymorph of fluvastatin sodium and a process for preparing it
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7368581B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
DE602004018494D1 (de) 2003-06-18 2009-01-29 Teva Pharma Fluvastatin-natrium in der kristallform xiv, verfahren zu deren herstellung, diese enthaltende zusammensetzungen und enstprechende anwendungsverfahren
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
US7432380B2 (en) 2003-10-16 2008-10-07 Ciba Specialty Chemicals Corp. Crystalline form of Fluvastatin sodium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
WO2006008656A2 (en) * 2004-07-21 2006-01-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Oatp-c gene c463a polymorphism underlies variable response of statin therapy
US7371906B2 (en) * 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
WO2006021967A1 (en) * 2004-08-26 2006-03-02 Biocon Limited Process for the preparation of fluvastatin sodium form a.
WO2006030304A2 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
CA2583312A1 (en) * 2004-10-05 2006-04-13 Biocon Limited Process for the preparation of amorphous fluvastatin sodium
US7795451B2 (en) * 2005-02-11 2010-09-14 Jubilant Organosys Limited Polymorphic forms of fluvastatin sodium and process for preparing the same
WO2006109147A1 (en) * 2005-04-12 2006-10-19 Glenmark Pharmaceuticals Limited Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same
CA2642180A1 (en) * 2006-02-27 2007-09-07 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium novel forms and preparation therof
DE602006006899D1 (de) 2006-04-20 2009-07-02 Italiana Sint Spa Verfahren zur Herstellung von Fluvastatin-Natrium
CN101250153B (zh) * 2008-02-26 2013-09-18 深圳信立泰药业股份有限公司 一种制备氟伐他汀钠晶型的工艺
PT2419407E (pt) * 2009-04-15 2013-01-28 Pharmathen Sa Processo melhorado para a preparação de fluvastatina e dos seus sais
CN114280181B (zh) * 2021-12-23 2024-06-18 浙江海翔川南药业有限公司 一种瑞舒伐他汀中间体及其有关物质的检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU204253B (en) * 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására

Also Published As

Publication number Publication date
WO1997049681A1 (en) 1997-12-31
US6124340A (en) 2000-09-26
DK0907639T3 (da) 2003-06-23
DE69719755T2 (de) 2003-11-20
PT907639E (pt) 2003-06-30
JP4282092B2 (ja) 2009-06-17
EP0907639A1 (de) 1999-04-14
CY2461B1 (en) 2005-06-03
JP2000512992A (ja) 2000-10-03
ES2194202T3 (es) 2003-11-16
AU3366297A (en) 1998-01-14
DE69719755D1 (de) 2003-04-17
EP0907639B1 (de) 2003-03-12
JP2009149654A (ja) 2009-07-09

Similar Documents

Publication Publication Date Title
ATE234282T1 (de) Polymorphe verbindungen
LU91751I2 (fr) Asenapin et ses dérivés pharmaceutiquement acceptables (SYCREST®)
IL116385A0 (en) Sulphonamides their manufacture and pharmaceutical compositions containing them
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
DE69831868D1 (en) Antithrombosemittel
HU9601218D0 (en) Distamycin a analogue utilizable as antitumoral and antiviral medicines
ATE381539T1 (de) Dipeptidylpeptidase-hemmer zur behandlung von diabetes
PL376822A1 (pl) Pochodne fenyloalaniny jako inhibitory dipeptydylopeptydazy do leczenia lub zapobiegania cukrzycy
SE9504661D0 (sv) New compounds
DE69830504D1 (de) Antithrombotische mitteln
DE60330485D1 (de) Zur behandlung von diabetes
HUT77925A (hu) Dihidrobenzofuránok, azokat tartalmazó gyógyászati készítmények és eljárás előállításukra
BR9611175B1 (pt) compostos e composiÇÕes farmacÊuticas.
AU2672995A (en) {a}-annelated pyrrole derivatives and pharmaceutical uses thereof
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
BR0111102A (pt) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4pip eridinometanol ou sua pró-droga no tratamento de sintomas de demência e psicose induzida por dopamina
DK0823909T3 (da) Hidtil ukendte heterocykliske forbindelser
ES2076838T3 (es) Nuevo derivado de la isoindolinona, su preparacion y las composiciones farmaceuticas que le contienen.
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
ES2156212T3 (es) Derivados de azabicicloheptano n-substituidos como neurolepticos, etc.
ES2140683T3 (es) Procedimiento para preparar compuestos de benzopirano.
GEP20084343B (en) Use of indole derivatives for the treatment of neuropathic pain
ES2123796T3 (es) Derivados de acidos fosfono-succinicos y su utilizacion como medicamentos.
AU2796695A (en) Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders
DE69824410D1 (en) Antithrombosemittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0907639

Country of ref document: EP